Skip to main content

Table 2 Association between EmiR expression at Ext2 and clinicopathological characteristics in LBC patients

From: Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

   Ext2
EmiR-21 EmiR-222 EmiR-221 EmiR-105 EmiR-155
n Median p value Median p value Median p value Median p value Median p value
Age (years) < 50 19 3.975 0.585 1.851 0.536 1.705 0.771 2.534 0.166 2.173 0.536
≥ 50 14 3.033 2.100 1.718 11.182 1.401
Menopause Pre 20 4.159 0.094 2.250 0.461 1.890 0.338 3.916 0.224 2.177 0.768
Post 13 2.192 1.551 1.422 10.603 1.507
T T1–T2 18 3.668 0.233 2.382 0.828 2.238 0.219 16.929 0.112 2.601 0.159
T3–T4 15 3.246 1.851 1.286 3.484 1.819
N 0 11 3.975 0.621 3.037 0.621 2.490 0.006* 21.588 0.445 1.344 0.928
1–3 18 3.477 2.250 1.095 8.885 2.177
Estrogen receptor Negative 8 2.133 0.450 1.213 0.475 1.095 0.585 5.405 0.529 0.839 0.120
Positive 25 3.933 2.649 2.000 11.760 2.173
Progesterone receptor Negative 11 2.192 0.541 1.338 0.760 1.787 0.541 7.327 0.789 3.224 0.849
Positive 22 3.668 2.250 1.686 8.528 1.899
HER2 Negative 27 3.933 0.031* 3.037 0.056 1.705 0.744 5.297 0.484 2.173 0.161
Positive 6 0.857 0.536 41.874 46.810 0.639
KI67 < 20% 6 4.996 0.427 1.464 0.283 0.321 0.176 3.691 0.963 1.355 0.191
≥ 20 27 3.246 3.037 1.787 10.444 3.201
Perou’s classification Basal-like 5 2.192 0.655 1.338 0.666 1.286 0.666 3.484 0.510 0.983 0.232
Luminal A 5 6.058 0.729 0.334 2.085 1.367
Luminal B 20 3.324 3.052 2.038 16.580 3.459
HER2neu 3 2.074 0.175 0.307 10.603 0.695
  1. Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext2 extraction during neoadjuvant treatment, T tumor size, N lymph node status. *p > 0.05